Financhill
Back

Novavax 10K Form

Sell
22

NVAX
Novavax

Last Price:
5.57
Seasonality Move:
7.55%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

Receive NVAX News And Ratings

See the #1 stock for the next 7 days that we like better than NVAX

NVAX Financial Statistics

Sales & Book Value

Annual Sales: $1.98B
Cash Flow: $-58.05M
Price / Cash Flow: 0
Annual Sales: $-5.71
Price / Book: 0

Profitability

EPS (TTM): -6.37000
Net Income (TTM): $-548.92M
Gross Margin: $1.08B
Return on Equity: 0%
Return on Assets: -29.16%

Novavax Earnings Forecast

Key Novavax Financial Ratios

  • The Gross Profit Margin over the past 24 years for NVAX is 54.46%.
  • The Selling, General & Administrative Expenses for NVAX have been equal to 24.66% of Gross Profit Margin.
  • The Research & Development expenses have been 62.33% of Revenue.
  • The Interest Expense is -3.02% of Operating Income.
  • The Net Earning history of NVAX is -33.20% of Total Revenues.
  • Per Share Earnings over the last 27 years have been positive in 12 years.

Novavax Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: NVAX
CUSIP: 670002
Website: novavax.com

Debt

Debt-to-Equity Ratio: -0.25
Current Ratio: 0.69
Quick Ratio: 0.53

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NVAX Technical Analysis vs Fundamental Analysis

Sell
22
Novavax (NVAX) is a Sell

Is Novavax a Buy or a Sell?

  • Novavax stock is rated a Sell
    The current Novavax [NVAX] share price is $5.57. The Score for NVAX is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.